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Introduction
The SIPPET (Survey of Inhibitors in Plasma-Products 
Exposed Toddlers) trial1 provided evidence that, in 
previously untreated patients with severe haemophilia A, 
recombinant factor VIII increases the risk of developing high-
titre inhibitors as compared with plasma-derived factor VIII. 
This multicentre, international study enrolled 264 previously 
untreated patients (mean age, around 20 months) who were 
randomised to receive either recombinant factor VIII or 
plasma-derived factor VIII. Inhibitors developed in 29/125 
patients treated with plasma-derived factor VIII (high-titre 
inhibitors: 20 patients) and in 47/126 patients treated with 
recombinant factor VIII (high-titre inhibitors: 30 patients). 
The cumulative rates of all inhibitors were 26.8% with 
plasma-derived factor VIII (high-titre inhibitors: 18.6%; 
95% confidence interval [CI]: 11.2 to 26.0) and 44.5% with 
recombinant factor VIII (high-titre inhibitors: 28.4%; 95% 
CI: 19.6 to 37.2). This implies that, in the SIPPET trial, the 
relative risk reduction for the incidence of high-titre inhibitors 
was 34.5% for plasma-derived factor VIII compared with 
recombinant products. All inhibitors occurred before 39 
exposure days; all high-titre inhibitors occurred before 34 
exposure days (median: 7 to 8 exposure days). 
These findings have important clinical implications, 
but their budget impact also deserves to be considered, 
particularly because of the high cost incurred in the 
treatment of high-titre inhibitors. In November 2015, 
we published a preliminary assessment on this topic 
based on the initial results of SIPPET and on a simple 
narrative analysis2. 
To address this issue better, in the present study we 
developed a Markov model and studied the economic 
consequences in terms of budget impact that, in 
previously untreated patients with severe haemophilia 
A, can derive from using plasma-derived products as 
opposed to recombinant factor VIII.
Materials and methods
Our analysis employed a Markov model based 
on the results of the SIPPET randomised trial and on 
clinical and economic information previously reported 
in the literature. Our study was designed as a budget-
impact analysis comparing previously untreated patients 
managed with plasma-derived factor VIII with those 
managed with recombinant factor VIII. The simulation 
model was developed using commercial software 
(TreeagePro, 2011 version; Treeage Software Inc., 
Williamstown, MA, USA). The main characteristics of 
the model are presented in Figure 1. 
Our analysis was from the payer's perspective and 
excluded indirect costs. All costs are expressed in euros. 
Economic data expressed in American dollars were 
converted into Euro according to an exchange rate of 
€ 1 = US$ 1.12. 
Briefly, the core of our model is a decision node (not 
shown in Figure 1) from which two branches originate, the 
first describing the patients assigned to recombinant factor 
VIII (panel A in Figure 1) and the second those assigned 
to plasma-derived factor VIII (panel B in Figure 1). A 
total of ten states of health were included in the Markov 
model (see our online supplementary material for details). 
In each of the two main sections of the model (i.e. 
recombinant factor VIII [panel A] and plasma-derived 
factor VIII [panel B]), the Markov analysis incorporated 
the adjustment for annual discount rates and traced the 
number of cycles evaluated in the iterative process.
The transition probabilities that manage how patients 
move across the health states are presented in panels A 
and B (Figure 1). Probabilities with values of 0 or 1 are 
self-explanatory; the symbol "#" identifies a probability 
equal to the value needed to reach 100% after taking into 
account the other probability/probabilities expressed in 
numerical form and assigned to the other branch(es) of 
the same node. 
According to the Markov approach, costs incurred 
in the model are iteratively summed upon each cycle. 
Three items participated in the cost analysis, namely 
the annual cost per patient treated with recombinant 
factor VIII (denoted as "annual_cost_ric"), the annual 
cost per patient treated with plasma-derived factor VIII 
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Figure 1 -  States of the Markov model and transition probabilities. 
 The starting point of the simulation model is a decision node (not shown in this figure) from which two branches originate, 
the first of which describing the patients assigned to recombinant factor VIII (panel A) and the second the patients assigned 
to plasma-derived factor VIII (panel B). The symbols adopted in this scheme reflect the syntax required by the Treeage 
software (    : Markov node; Ο: probabilistic node ;    : terminal node). 
 RIC: recombinant; PD: plasma-derived; IT: immune tolerance; _STAGE: yearly cycle in Markovian simulations; RWD: 
reward (i.e. the variable expressing the cumulative cost).
Table I - Model parameters employed in our base-case analysis*.
Item Model parameter Value References 
#1 Cost for each patient developing high-titre inhibitors € 891,500* Maratea et al. 20163 
Colowick et al. 20004
#2 Annual cost per patient of treatment with recombinant factor VIII  € 50,000 Based on expert opinion†
#3 Annual cost per patient of treatment with plasma-derived factor VIII expressed as percent 
reduction in comparison with the cost of using recombinant factor VIII
−20% Based on expert opinion†
#4 Time horizon (years) 15 Based on expert opinion†
#5 Annual discount rate 3% Abrahamyan et al. 20145
#6 Increased incidence of high-titre inhibitors with recombinant factor VIII compared 
with plasma-derived factor VIII
9.8%** Peyvandi et al. 20161
*Cost values expressed in US$ were converted into € according to an exchange rate of 1 € = 1.12 US$; **Calculated from 28.4% with recombinant factor 
VIII vs 18.6% with plasma-derived factor VIII; †These values were decided by consensus among FP, RP, FRR, and PMM in the absence of any explicit 
reference, but taking into account the published literature.
(denoted as "annual_cost_pd"), and the cost per patient 
of immunotolerance therapy (denoted as "cost_of_IT"). 
As regards the syntax of the Treeage software, cost data 
were handled as "incremental rewards" (denoted as "Incr 
Rwd"). In other words, the variable "Rewards" was used 
to cumulate the various cost data at each cycle.
The variables included in our model reflect the main 
determinants likely to influence our budget-impact analysis. 
In the base-case analysis, all cost data were discounted at 
3% yearly; the time horizon was set at 15 years. 
In modelling the pattern of costs associated with 
the two types of factor VIII replacement therapy, the 
following variables were assumed to differ between 
the two cohorts of patients: (i) cumulative incidence of 
high-titre inhibitors (data obtained from the results of 
SIPPET); (ii) cost of treatment using plasma-derived or 
recombinant factor VIII products (data obtained from 
literature). Other variables were assumed to be the same 
for the cohorts (e.g. induction of immune tolerance and 
respective costs; time horizon; discount rate). Table I 
presents the values that, in our base-case analysis, were 
assigned to the main parameters of the model, along with 
the sources of these pieces of information. A series of one-
way sensitivity analyses was performed to assess how 
the variations of the main model parameters influenced 
the economic results of our analysis (Table II). 
Finally, it should be noted that the age and the 
average body weight of toddlers included in the SIPPET 
trial were lower than the typical values found in adult 
patients with haemophilia. It is well known that the cost 
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of treatment with factor VIII is very strongly dependent 
on age and weight, as factor VIII requires weight-based 
dosing. However, given the budget-impact nature of our 
analysis, we did not introduce any sensitivity analysis 
focused on age and/or body weight because we chose to 
directly vary the annual cost of the replacement therapy 
(which is a direct consequence of the dosage adopted); a 
wide range of variation in this annual cost was therefore 
evaluated because the goal of our sensitivity analysis on 
this variable was also to test the effect of age and weight.
The presentation of our analysis is in line with most 
of the recommendations of the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) 
described by Husereau and co-workers10. 
Results 
Our base-case analysis (time horizon: 15 years) 
estimated an average cost per patient of € 846,829 for 
the recombinant factor VIII cohort and of € 644,782 for 
the plasma-derived factor VIII cohort. The difference 
between these two treatment options was € 202,047 per 
patient over 15 years.
The results of our one-way sensitivity analyses are 
presented in Table II (columns 1 to 6). In testing the 
hypothesis of no difference in cost per international 
unit (IU) between the two types of factor VIII, analysis 
#3 (estimate N. 1) found a cost increase of about € 
120,000 per patient over 15 years, which is lower 
than the value of about € 200,000 found in our base-
case analysis. This indicates that this latter value of 
cost increase is due to a remarkable extent (~60%) 
to the higher cost per unit of recombinant factor VIII 
and to a lesser extent (~40%) to the consequences 
of the increased incidence of high-titre inhibitors 
with recombinant products. Accordingly, testing 
the variations from +5% to +15% for the increased 
incidence of high-titre inhibitors with recombinant 
factor VIII (analysis #6) showed a modest effect on 
the cost increase per patient between the two types 
of factor VIII, because this increase ranged from € 
162,000 to € 243,000 (in comparison with € 202,000 
of the base-case analysis). Varying the cost of immune-
tolerance therapy from € 338,700 to € 1,200,00 (analysis 
#1) resulted into estimates of cost increase ranging 
from € 149,000 to € 232,000. On the other hand, the 
highest value of the increase in the cost per patient (€ 
548,180) was associated with the assumption (analysis 
#2, estimate N. 6) that the annual cost per patient 
treated with recombinant factor VIII was € 183,673 (as 
compared with the assumption of € 50,000 adopted in the 
base-case analysis). In analysis #2, it is noteworthy that 
the hypothesis of a reduced annual cost of recombinant 
factor VIII (€ 30,000; estimate N. 1) was associated 
with a cost increase of € 198,160, which remains close 
to the base-case result; this hypothesis in part reflects 
the reduced dosage administered to toddlers, with a 
consequent reduction in annual cost. 
Finally, analyses #4 and #5 (focused on variations in 
time horizon and discount rate) indicated that these two 
parameters had no important effect on the overall results. 
Discussion
In the light of the results of SIPPET trial, the 
present study addressed an issue for which no specific 
data were available, but numerous questions are open. 
If recombinant products of factor VIII generate an 
increased incidence of inhibitors, are there any budget 
implications? To what extent is the overall cost per 
patient increased using recombinant products as opposed 
to plasma-derived ones? 
The present analysis has expanded previous 
preliminary research conducted on this issue2 and has 
one important advantage in that a specific simulation 
model was developed and applied to generate the 
pharmacoeconomic results. In our previous narrative 
analysis, we observed that, in the comparison between 
recombinant and plasma-derived factor VIII, the number 
needed to harm (NNH) was around 10 according to 
the results of SIPPET. In estimating the NNH (as well 
as the number needed to treat), results are known to 
be less biased if the analysis is based on the relative 
risk reduction (−34.5%) as opposed to the absolute 
risk reduction. If one applies a relative risk reduction 
of −34.5% to the incidence of 28.4% observed for 
recombinant products in SIPPET, the absolute risk 
difference (around −10%) yields a NNH around 10, as 
pointed out above. However, if one applies the relative 
risk reduction of −34.5% to other incidences of high-titre 
inhibitor development in patients given recombinant 
products (e.g. the incidences of 17.6 and 22.4% reported 
by Di Minno and co-workers11), the absolute risk 
differences are around −6.1 and −7.7%, respectively, 
and the corresponding values of NNH are 16.5 and 
12.9, respectively. Hence, assuming an absolute risk 
difference around −6% and a NNH around 17 identifies 
a reduced monetary advantage which is approximately 
the value (increase of € 162,014 in the cost per patient) 
estimated in our sensitivity analysis #6 for an absolute 
risk difference of −5%.
From an economic viewpoint, this means that the use 
of recombinant factor VIII is associated with an average 
increase in the treatment cost per patient equal to the 
average cost of treating one case of high-titre inhibitors 
divided by 10. This in turn raises the need to estimate 
the average cost to treat one patient who develops high-
titre inhibitors, which we conservatively assumed to be 
€ 338,770 (even though estimates as high as € 800,000 
have been reported in the literature). Dividing the above 
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(i.e. € 338,770) by 10 yields € 33,877 per patient. Hence, 
we conservatively concluded that the increase in cost 
was at least € 33,877 per patient if recombinant factor 
VIII is used instead of plasma-derived factor VIII. 
The analysis described herein had a more complete 
design, assumed a longer time horizon, incorporated 
a rather large number of relevant variables and, most 
importantly, addressed these economic questions using 
a well-recognised instrument of data simulation. The 
results of our analysis estimated a much higher increase 
in per-patient cost (i.e. around € 200,000) if recombinant 
factor VIII is used instead of plasma-derived factor VIII. 
Our study has limitations. First of all, despite 
its apparent complexity, our simulation model was 
a simplified one and only accounted for the main 
determinants influencing cost, whereas other variables 
were not considered (e.g. the timing expressed as 
exposure days at which inhibitors could develop). Some 
variables were not introduced in the model. For example, 
immune tolerance induction is usually performed in 
Europe using the same factor being given to the patient 
when the inhibitor developed12. Our model did not 
account for this criterion of factor VIII selection, but 
the wide range of expenditures for immune tolerance 
induction tested in our sensitivity analysis was likely 
to compensate for this lack of modelling.
Our model did not directly address the issue of the 
cost per unit of factor VIII, and so an in-depth discussion 
of this point is worthwhile. In the base-case analysis, our 
model incorporated a cost per unit of recombinant factor 
VIII of € 0.656,9; this corresponds to a yearly amount 
of factor VIII per patient of around 46,000 IU. In the 
sensitivity analysis, this amount per patient per year was 
subjected to numerous upward variations and reached a 
maximum of more than 282,000 IU (Table II, analysis 
#2). Under the assumption of 100 or 150 administrations 
per patient per year, each administration consisted, on 
average, of 461 IU and 308 IU, respectively. Finally, 
since the time horizon of the analysis covered a total 
of 20 years and consequently the body weight of the 
simulated patients increased over this period, it should 
be stressed that numerous model-predicted parameters 
(including those presented above) represent an average 
in a context in which important variations are determined 
by the increase over time in the patients' body weight.
Another limitation of our study is that the range 
of values over which variations were assumed in 
the sensitivity analyses were sometime not based 
on specific information published in the literature, 
but rather reflected some assumptions made by 
consulting the co-authors of SIPPET, experienced in 
the treatment of haemophilia. Although the lack of 
some data in explicit form is, of course, a drawback 
to our study, it should be noted that this approach is 
frequent when a deterministic sensitivity analysis is 
undertaken. 
We did not employ a lifetime horizon because 
predicting which treatments will be the standard of care 
for so many years (including replacement therapies and 
immuno-tolerance), and also predicting their future 
costs, would have increased the degree of uncertainty 
of our analysis. Likewise, we did not adjust the model 
based on the patients' life expectancy because this 
adjustment has a negligible impact, particularly if the 
time horizon is restricted to 15 years3. 
Another limitation is that, because patients included 
in the SIPPET trial were generally toddlers, assumptions 
about their body weight and the daily units of replacement 
factor VIII were difficult. This limitation was addressed by 
extending to six the values of annual cost of replacement 
factor VIII tested in sensitivity analyses. 
Conclusions
The clinical implications raised by the randomised 
SIPPET trial on the choice of the less immunogenic 
source of factor VIII obviously remain the main focus, 
even in the framework of the present economic study. 
However, analysing the economic aspects, the use of 
recombinant factor VIII as opposed to plasma-derived 
products implies a relevant increase in the expenditure 
per patient (about € 200,000 over 15 years). This 
increased expenditure directly reflects the increased 
cost of recombinant products, in comparison with 
plasma-derived ones, and the economic consequences 
of the expected increase in the incidence of inhibitors in 
previously untreated patients with severe haemophilia A.
Finally, while in recent years innovative recombinant 
factor VIII products have been developed (e.g. enhanced 
half-life factor VIII products and factor VIII mimetics), 
the present analysis applies only to "traditional" plasma-
derived or recombinant factor VIII products and not to 
the above-mentioned innovations.
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